Patients welcome new non-steroid treatment for atopic eczema

August 28, 2003 09:20 ET | Source: Novartis Pharma AG Novartis Pharma AG

For release content, please refer to the attachment.

Attachments

122433.pdf...

Recommended Reading

September 08, 2026 01:00 ET | Source: Novartis Pharma AG

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

Ad hoc announcement pursuant to Art. 53 LR HARBOR did not meet its primary endpoint of vHOT in DM1, a progressive neuromuscular disease with high unmet need and no approved treatment options ...
Read More
September 04, 2026 16:30 ET | Source: Novartis Pharma AG

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Ad hoc announcement pursuant to Art. 53 LR Basel, September 4, 2026 – Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not...
Read More